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ORIGINAL ARTICLE
The vaccine potential of Bordetella pertussis
biofilm-derived membrane proteins
Daan de Gouw1,2, Diego O Serra3, Marien I de Jonge1,2, Peter WM Hermans1,2, Hans JCT Wessels4,
Aldert Zomer1,2, Osvaldo M Yantorno3, Dimitri A Diavatopoulos1,2 and Frits R Mooi1,2,5
Pertussis is an infectious respiratory disease of humans caused by the gram-negative pathogen Bordetella pertussis. The use of
acellular pertussis vaccines (aPs) which induce immunity of relative short duration and the emergence of vaccine-adapted strains are
thought to have contributed to the recent resurgence of pertussis in industrialized countries despite high vaccination coverage. Current
pertussis vaccines consist of antigens derived from planktonic bacterial cultures. However, recent studies have shown that biofilm
formation represents an important aspect ofB. pertussis infection, and antigens expressed during this stagemay therefore be potential
targets for vaccination. Here we provide evidence that vaccination of mice with B. pertussis biofilm-derived membrane proteins
protects against infection. Subsequent proteomic analysis of the protein content of biofilm and planktonic cultures yielded 11 proteins
which wereothree-fold more abundant in biofilms, of which Bordetella intermediate protein A (BipA) was the most abundant,
surface-exposed protein. As proof of concept, mice were vaccinated with recombinantly produced BipA. Immunization significantly
reduced colonization of the lungs and antibodies to BipA were found to efficiently opsonize bacteria. Finally, we confirmed that bipA is
expressed during respiratory tract infection of mice, and that anti-BipA antibodies are present in the serum of convalescent whooping
cough patients. Together, these data suggest that biofilm proteins and in particular BipA may be of interest for inclusion into future
pertussis vaccines.
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INTRODUCTION
The gram-negative bacterium Bordetella pertussis is themain causative
agent of whooping cough or pertussis. During epidemics in the pre-
vaccination era, pertussis was attributable for up to 13% of all-cause
child mortality (f10 years).1 While this percentage has dropped sig-
nificantly following the introduction of widespread vaccination in the
1950s, pertussis has resurged since the 1990s2,3 and is now estimated to
(re-)infect 40 million people each year,3–5 resulting in approximately
195 000 deaths worldwide, mainly in children.6
Although acellular pertussis vaccines (aPs) are highly effective in
protecting infants from developing severe pertussis, immunity already
wanes after 5–10 years 7,8 and aPs may not effectively reduce circula-
tion of B. pertussis in the population.9 This may have facilitated the
evolution of antigenically divergent strains and, more recently, the
emergence of a lineage (designated the P3 lineage) that produces
higher amounts of several virulence factors, including pertussis toxin
(Ptx).10,11 Alarmingly, within this P3 lineage, strains that do not
express pertactin (Prn), a component of most aPs, have emerged in
the last six years and are now becoming increasingly dominant.12–14
Clearly, there is a need for novel antigens for inclusion in pertussis
vaccines to improve their effectiveness. Here we have focused on bio-
films as a potential source of protective antigens.
B. pertussis is able to produce biofilms in the respiratory tract and
this process has been shown to contribute to successful infection.15–18
In general, biofilm-associated bacteria differ significantly from their
planktonic counterparts 19 and studies with B. pertussis have shown
that ,10% of the proteome is differentially expressed between these
conditions.20 Most B. pertussis proteins that interact directly with
the host are regulated by the two-component Bordetella master
virulence regulatory system BvgAS which transduces environmental
signals such as temperature, nicotinic acid and sulfate, to gene
regulation (reviewed in Decker et al.21). Based on the activity of
this system, the Bvg1, Bvgi, and Bvg2 phase have been defined. In
the Bvg1 phase, almost all virulence factors are expressed.10,21 The
Bvgi phase, characterized by the expression of the Bordetella inter-
mediate protein A (BipA), has been suggested to be involved in
transmission and biofilm formation.22–24 Bvg1 and Bvgi phase bac-
teria have been shown to be virulent in mice, whereas Bvg2-locked
bacteria, which cannot switch to the Bvg1 or Bvgi phase, are unable
to establish infection.24,25
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Here we examined the ability of B. pertussis biofilms to protect
against pertussis using amouse model. Having confirmed the protect-
ive potential of biofilms, we then comprehensively analyzed the bio-
film antigenic protein composition and compared it to in vitro
planktonic grown bacteria. Finally, we evaluated whether immuniza-
tion with a single biofilm protein, BipA, was able to protect mice
against respiratory infection with B. pertussis and examined the
expression of bipA during infection.
MATERIALS AND METHODS
Ethics statement
Animal experiments were approved by the Radboudumc Committee
for Animal Ethics and conducted in accordance with the relevant
Dutch legislation. Bacterial strains were collected by regional
Medical Microbiology Laboratories from patients suspected of
whooping cough and sent to the National Institute for Public
Health and the Environment in the context of routine surveillance
(as required by law). The strains were sent to the National Institute
for Public Health and the Environment for confirmation of clinical
diagnosis, species determination and subtyping. Strictly anonymized
patient information was included, which was limited to age, sex and
postal code. For this type of surveillance, ethical evaluation or patient
consent are not required. The strains have been used in previous
studies.10
Bacterial strains and growth conditions
For flow cytometry and quantitative polymerase chain reaction ana-
lysis, B. pertussis strains were grown under Bvg1, Bvgi and Bvg2 con-
ditions as described previously.10 For modulation of the BvgAS
regulatory system, magnesium sulfate was added to cultures at a final
concentration of 5 mM and 50 mM to induce Bvgi and Bvg2 condi-
tions, respectively. In the absence of additional sulfate, the concentra-
tion of free sulfate is 0.02 mM, thereby inducing Bvg1 conditions. For
proteomics, B. pertussiswas grown under planktonic and biofilm con-
ditions in chemically defined THIJSmedium26 essentially as described
previously.20 Briefly, planktonic cultures were grown overnight in
chemically defined THIJS medium supplemented with 0.2 mg/mL
Heptakis-cyclodextrin (Sigma-Aldrich Chemie B.V., Zwijndrecht,
The Netherlands) and then re-inoculated into pre-warmed medium
at an optical density at 620 nm (OD620) of 0.075. Planktonic cultures
were harvested by centrifugation (156C, 8000g, 20 min) at mid-expo-
nential (17 h) and stationary (40 h) growth phases, washedwith phos-
phate-buffered saline (PBS) and snap-frozen in liquid nitrogen.
Biofilm cultures were carried out by using glass column reactors (dia-
meter: 6 cm, h545 cm; Industria Vidriera Argentina, SA, Buenos
Aires, Argentina) packed with flat polypropylene beads (300 g; dia-
meter: 4.1 mm, h51.5 mm, with an average density of 0.901 g/cm3;
Pentroken, Buenos Aires, SA, Argentina), which served as growth
support. The bioreactors were inoculated with 200 mL of a planktonic
culture of B. pertussis B1917 (OD620 of 1.0) grown in THIJS medium
and incubated for 5 h at 376C to allow bacterial attachment to the
beads. Then, the suspension was drained to remove unattached cells
and 200 mL of fresh THIJS medium was added to each column.
Bioreactors were incubated aerobically (0.1 L/min) at 376C and the
THIJS medium was refreshed at 24-h intervals. For proteomic ana-
lysis, biofilm cells were harvested after 72 h, when the biofilm achieved
its mature structure. Beads were washed three times with sterile PBS
buffer to remove unattached cells. Sessile cells were gently detached
from beads by slight agitation in PBS buffer, pelleted by centrifugation
8000g for 20 min at 156C, washed twice and snap-frozen in liquid
nitrogen. Sessile cell pellets were stored at 2806C and freeze-dried
for protein isolation.
Escherichia coli OverExpress C41(DE3) (Lucigen, Middleton, WI,
USA), used for rBipA expression, was grown in Luria Bertani medium
containing appropriate antibiotics (ampicillin, kanamycin and/or
chloramphenicol at a concentration of 50 mg/mL) at 376C.
Proteomics analysis
Bacterial pellets from 10 mL of planktonic (mid-exponential or sta-
tionary) or biofilm cultures were lysed by sonication and used for the
isolation of cytosolic and membrane protein fractions using the
ReadyPrep Protein Extraction Kit Membrane I (Bio-Rad Labora-
tories, Hercules, CA, USA). The obtained soluble and insoluble frac-
tions, respectively containing the cytosolic andmembrane (-associated)
proteins were purified using the ReadyPrep 2-D clean-up Kit (Bio-Rad
Laboratories). Finally, protein pellets were dissolved in 8 M urea in
10 mM Tris-HCl pH 8.0 and subjected to in-solution digestion and
C18 reversed phase nano flow liquid chromatography-mass spectro-
metry/mass spectrometry analysis as described in Supplementary
Information. For vaccination experiments, membrane proteins were
diluted in PBS as described below.
Recombinant BipA production
The entire DNA sequence of the bipA (BP1112) gene lacking the N-
terminal signal sequence (amino acids 1–20) andmembrane spanning
domain (amino acids 21–66) was codon optimized for expression in E.
coli, synthesized by GenScript (GenScript USA Inc. Piscataway, NJ,
USA), and cloned into pET28-TEVsite vector (modified from pET28a
vector; Novagen, Madison, WI, USA) to generate an N-terminally
His6-tagged BipA protein (rBipA). rBipA expression from the
pET28-TEVsite vector was induced in E. coli OverExpress C41(DE3)
(Lucigen) cultured to OD60050.6–0.7 at 376C by addition of 1 mM
isopropyl b-D-1-thiogalactopyranoside for 3 h. Induced cultures were
harvested by centrifugation (4000g for 15 min at 46C) and enzymati-
cally lysed by resuspending the pellet in Bacterial Protein Extraction
Reagent (Thermo Scientific, Waltham, MA, USA) containing 25 U/
mL benzonase nuclease (Novagen), 100 mg/mL lysozyme, and prote-
ase inhibitors (Roche, Mannheim, Germany), and incubating for 30
min at room temperature. The cells were disrupted further by sonicat-
ing the bacterial solutions (30 s pulse for 5min at an intensity of 70%).
Cell lysates were centrifuged (4000g for 30 min at 46C) and pellets
containing inclusion bodies dissolved in a buffer containing 20 mM
sodium phosphate, 500 mM NaCl, 4 M urea and 20 mM imidazole
and used for protein purification. His6-tagged rBipA was purified on a
AKTA FPLC system using affinity chromatography on a HisTrap FF
crude 1 mL column prepacked with Ni Sepharose 6 Fast Flow (GE
Healthcare, Uppsala, Sweden). Bound rBipAwas eluted in a single step
elution with a buffer containing 20 mM sodium phosphate, 500 mM
NaCl, 4 M urea and 500 mM imidazole. Fractions containing rBipA
were pooled and protein concentrations were determined using the 2-
D Quant Kit according the manufactures protocol (GE Healthcare,
Uppsala, Sweden). rBipA was refolded by rapid 50-fold dilution in
10 mM Benzamidine, 1 mM EDTA, 100 mM NaCl and 50 mM Tris-
HCL (pH 8.8) as described.27
Protein samples obtained after isopropyl b-D-1-thiogalactopyrano-
side induction, cell lysis, and purification were analyzed on 10%
sodium dodecyl sulfate–polyacrylamide gel electrophoresis gradient gels
using Colloidal Coomassie staining and immune blotting. Colloidal
Coomassie staining was performed as previously described.28 Briefly,
sodium dodecyl sulfate–polyacrylamide gel electrophoresis gels were
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incubated for 3 h in staining solution consisting of 5% aluminum sulfate
14–18 hydrate, 10% ethanol, 0.02% of Coomassie Brilliant Blue G-250
and 8% phosphoric acid. Then, gels were destained by incubation for
30 min in 2% phosphoric acid and 10% ethanol and overnight incuba-
tion in water. For immune blotting, proteins were transferred to poly-
vinylidene difluoride membranes, blocked with PBS with 0.1% Tween-
20, 2% skim milk powder and 1% bovine serum albumin (BSA) (1 h at
room temperature) and incubated overnight with a 1 : 2000 diluted
Penta-His Antibody (Qiagen, Hilden, Germany) at 46C. After washing
three times for 5 min in PBS with 0.1% Tween-20, the membrane was
incubated for 1 h at room temperature with a goat-anti-mouse light
chain Horseradish peroxidase (HRP) antibody and washed again in a
similar manner. Finally, immunoblots were developed using an
enhanced chemiluminescence substrate system (GE Healthcare,
Uppsala, Sweden).
Vaccination
Individual groups of naı¨ve, female 6–8 week old BALB/c mice (Charles
River, Leiden, The Netherlands) were immunized subcutaneously on
day 0 and 14 with 5 mg rBipA or 1 mg purified membrane proteins
derived from planktonic or biofilm bacteria, mixed 1 : 1 in 1.3% alum
adjuvant (Sigma-Aldrich Chemie B.V. Zwijndrecht, The Netherlands).
As a negative control, mice were immunized with a similar ratio of PBS
and Alhydrogel, or with PBS alone. In order to compare efficacy to
current aPs, one group of mice was immunized with 1/50th of the
human dose (equals 1.16 mg of B. pertussis protein) of the commercial
hexavalent acellular pertussis vaccine Infanrix (25 mg Ptx, 25 mg fila-
mentous hemagglutinin (FHA), 8 mg pertactin; GSK, Rixensart,
Belgium). On day 35, mice were challenged by intranasal infection
with B. pertussis strain B1917 (23107 colony forming units (CFU) in
a total volume of 40 mL). On day 38 and 42, the bacterial load in the
nasopharynx (upper respiratory tract) and the lungs (lower respiratory
tract) was determined as described previously.29 Serial dilutions of the
nasal lavages (NLs) and lung homogenates were plated onto Bordet
Gengou agar plates and incubated at 376C for 3–4 days, after which the
bacterial load was determined. Serum samples were collected on days 0,
28, 38 and 42.
In vivo transcriptional analysis
Groups of 4 female BALB/c mice (6–8 weeks old) were infected intra-
nasally with B. pertussis strain B1917 as described above. Mice were
sacrificed after seven days, after which bacteria were collected from the
lungs through a bronchoalveolar lavage with PBS and RNA was sta-
bilized with 2 volumes of RNA Protect Bacteria Reagent (Qiagen).
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) and
contaminating genomic DNA was removed by DNase treatment
(Ambion, Carlsbad, CA, USA). Bacterial RNA was enriched and amp-
lified using the MICROBEnrich (Ambion) and SensationPlus FFPE
Amplification (Affymetrix, Santa Clara, CA, USA) Kits, respectively.
Enriched RNA was reverse transcribed using the SuperScript One-
Cycle cDNA Kit (Invitrogen, Carlsbad, CA, USA) and used for quant-
itative real-time PCR analysis. To determine relative expression levels,
DCt values were calculated by subtracting the Ct value of the recA
(BP2546) household gene from the Ct value of the target gene.
30 The
transcription data are expressed as 402DCt value, with 40 represent-
ing the number of PCR cycles as detection limit. A 402DCt value of 40
indicates that the gene is expressed at equal levels as recA, while lower
values correspond to lower expression.
Antibody analysis
Protein ELISA. IgG titers against rBipA in mouse and human sera
were determined by enzyme-linked immunosorbent assay (ELISA)
analysis. Microtiter plates (F96, MaxiSorp; Thermo Scientific,
Waltham, MA, USA) were coated with 2 mg/mL rBipA in 50 mL PBS
per well overnight at 46C. Control ELISAs were performed with plates
coated with 2 mg/mL Ptx in PBS (Kaketsuken, Kumamoto, Japan).
Plates were washed with PBSwith 0.05%Tween 20 and then incubated
for 1 h with PBS containing 1% BSA. Serial dilutions of mouse or
human sera were added to the plates and incubated for 1 h at 376C.
After washing, alkaline phosphatase (AP)-conjugated secondary goat
antibody directed to mouse IgG-Fc (Sigma-Aldrich) or human IgG
(Southern Biotech, Birmingham, AL, USA) was added for 1 h at 376C
using a 1 : 2500 and 1 : 1000 dilution, respectively. After washing,
50 mL per well of p-nitrophenyl phosphate (1 mg/mL) in substrate
buffer (10 mMdiethanolamine and 0.5 mMmagnesium chloride, pH
9.5) was added and the absorbance was read at 405 nm. IgG concen-
trations in mouse serum were determined using absorbance data of a
standard curve of 1–64 ng mouse IgG1 (Sigma) on wells coated with
2 mg/mL Rat anti-mouse Ig, kappa light chain (BD Pharmingen, San
Jose, CA, USA). Human serum titers were calculated by multiplying
the highest dilution with an optical density.0.2 with the correspond-
ing dilution factor, as a value .0.2 falls within the linear range of the
ELISA curve.
Whole-cell ELISA. Binding of IgG1, IgG2a and IgG2b to whole bacteria
was measured using a whole-cell ELISA method adapted from Abdillahi
and Poolman.31 Briefly, ELISA plates were coated with Bvg1 mid-log
culture of strain B1917 suspended in PBS, washed (PBS containing
0.05% Tween 20), blocked with 1% BSA/PBS, and incubated with serial
dilutions of mouse serum. After washing, ELISA plates were incubated
with HRP-conjugated rat-anti-mouse IgG1 (1 : 50 000 dilution; BD
Pharmingen, San Jose, CA, USA), HRP-conjugated rat-anti-mouse
IgG2a (BD Pharmingen; 1 : 10 000 dilution), or AP conjugated rat-
anti-mouse IgG2b (1 : 2000 dilution; Southern Biotech, Birmingham,
AL, USA) for 1 h at 376C. 3,39,5,59-tetramethylbenzidine substrate was
added to each well for the HRP-conjugated antibodies, while p-nitro-
phenyl phosphate substrate was used for AP-conjugated rat-anti-mouse
IgG2b. Optical density was then measured on an ELISA plate reader
(Tecan Infinite F50) at 450 and 405 nm for 3,39,5,59-tetramethylbenzi-
dine and p-nitrophenyl phosphate substrate, respectively. Antibody sub-
type concentrations were determined by comparison to standard curves
with known concentrations of each IgG subtype.
Opsonization. 1% BSA/PBS was used for all dilutions. 106 CFU of
Bvg1 and Bvg2 B1917 were incubated with serum orNL samples from
vaccinated mice for 30 min at 46C. Bacteria were fixed in 2% para-
formaldehyde and surface-bound IgG or IgA was detected using
anti-mouse IgG-Fc or IgA a-chain-FITC-conjugated antibodies (Sigma-
Aldrich) on a BD LSRII flow cytometer (Biosciences, San Jose, CA,
USA). The amount of surface-bound antibodies was expressed in
arbitrary units as a fluorescence index (FI), calculated by multiplying
the geometric mean fluorescence intensity by the percentage of FITC-
positive bacteria.32 Data were analyzed using FlowJo version 7.6.5
(TreeStar Inc, Ashland, OR, USA).
Statistical analyses
A two-tailed Mann–Whitney U test was used for comparison of
bacterial load in NL and lung homogenate samples between PBS-
vaccinated mice and rBipA or membrane protein-vaccinated mice.
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A Kruskal–Wallis test followed by a Dunns post-hoc test (a55%) was
used for comparison of antibody-mediated opsonization by serum
and NL sample between PBS-vaccinated mice and rBipA-vaccinated
mice. A one-tailed Wilcoxon signed-rank test was used to determine
whether ELISAmeasured IgG levels were significantly above the detec-
tion limit. All statistical analyses were performed using the GraphPad
Prism software program, version 5.0, where P,0.05 was considered
significant.
RESULTS
Membrane-associated proteins derived frombiofilms or planktonic
grown cells confer protection against respiratory tract infection in
mice
To evaluate the potential of biofilm-grown bacteria to confer protec-
tion against respiratory tract infection in mice, we cultured a B. per-
tussis clinical isolate (B1917, isolated in 2000) under biofilm-forming
and planktonic conditions. This particular strain belongs to the P3
lineage which emerged in the 1980s and currently predominates in
many vaccinated populations.33 For planktonic conditions, bacteria
were grown to mid-log and stationary phase. Following growth, bac-
teria were harvested and cytosolic and membrane (-associated) pro-
teins were extracted.34 The membrane fractions were adjuvanted with
Alhydrogel and the equivalent of 1 mg of protein was used to vaccinate
female BALB/cmice 23 by subcutaneous injection, with 2-week inter-
vals. In parallel, groups of mice were vaccinated with a currently
licensed three-component aP (Infanrix) or mock-vaccinated with
PBS or adjuvant only. Immunizedmice were then challenged by intra-
nasal infection with strain B1917, after which the lung and nose bac-
terial load was determined three and seven days later. Mice vaccinated
with aP showed a significant reduction (.220-fold) in lung CFUs at
day 3 and day 7 (Figures 1A and 1B). At three days following infection,
significant protection was observed in the lungs of mice immunized
with proteins derived from planktonic as well as biofilm-grown bac-
teria (Figure 1A). After seven days, protection was more pronounced,
with 29-fold, 43-fold and 170-fold reduction in bacterial load in mice
immunizedwith biofilm,mid-log and stationary proteins, respectively
(Figure 1B). The differences in protection induced by the three mem-
brane fractions were not significant. Of note, we observed that none of
the vaccinated mice, including those vaccinated with aP, were pro-
tected against infection with B. pertussis in the upper respiratory tract
(Figures 1C and 1D). Taken together, these data suggest that immun-
ization with biofilms can induce protection against infection.
Proteomic analysis of B. pertussis grown under biofilm or
planktonic conditions
As our initial results implied that biofilms contain protective antigens,
we compared the proteome of cytosolic and membrane protein frac-
tions of the mid-log, stationary and biofilm cultures by mass spectro-
metry, as described in Supplementary Information. This approach
identified a total of 749, 729 and 825 proteins in the extracts from
mid-log, stationary and biofilm cultures, respectively, with an overlap
of 645 proteins (88%). This analysis covered 21%–24% of the predicted
total of 3449 protein-coding open reading frames in the B. pertussis
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Figure 1 Immunization with membrane protein fractions derived from biofilm and mid-log and stationary planktonic cultures. Naive adult female BALB/c mice were
subcutaneously immunized with 1 mg membrane proteins. Negative controls consisted of adjuvant only (Alum) and PBS, while an acellular vaccine (aP) containing 0.5 mg
Ptx, 0.5 mg FHA and 0.16 mg Prn was used as a positive control. Subsequently, micewere infected intranasally with 23107 CFU ofB. pertussis strain B1917. The bacterial
load in the lungs and nose was quantified three (A and C) and seven (B and D) days after challenge. Each symbol represents one mouse. Horizontal lines represent the
mean. Dashed lines indicate the lower limit of detection. **P,0.005 relative to PBS mice; two-tailed Mann–Whitney U test. FHA, filamentous hemagglutinin.
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genome.35 IDEAL-Q36 was then used to identify proteins which were
differentially regulated in biofilms (Supplementary Information). This
method normalizes and quantifies comparable peptides between parallel
runs of different samples.36 Proteins that wereothree-fold more or less
abundant under biofilm (either cytoplasmic or membrane fraction) con-
ditions compared to either mid-log or stationary conditions, were
defined as biofilm-upregulated and biofilm-downregulated proteins,
respectively. This strategy yielded 60 biofilm-upregulated proteins.
Aggregation based on function and predicted subcellular localization
showed that these proteins were significantly enriched for (ribosomal)
proteins involved in protein synthesis (N517, 27.4%, P57.731024;
Figure 2 and Supplementary Table S1). Additionally, 48 proteins were
identified which were downregulated in biofilms. While this set of pro-
teins was not significantly enriched for any specific functional classes, 17
of these proteins have previously been identified as Bvg-activated genes
in strain B1917,10 including the virulence factors Vag8, FimX, and eight
type III secretion system (T3SS) proteins (Supplementary Table S1).
Vaccine candidate antigen selection
We focused on the 11 proteins that were upregulated in biofilms
compared to both mid-log and stationary planktonic conditions, as
these potentially represent protein antigens specifically expressed in
biofilms. These proteins were ranked based on protein abundance,37,38
as well as predicted surface accessibility (i.e., outer membrane or
extracellular)39 (Table 1). Protein abundance was estimated for each
fraction and growth condition by emPAI score,37,38 a method which
provides an approximate protein ranking based on the number of
observed peptides per protein relative to the number of observable
peptides (Supplementary Table S2). Based on these criteria, BipA was
identified as the most abundant surface-associated biofilm protein.
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Figure 2 Functional clustering of proteins identified with proteomics. 645 proteins were identified under all three growth conditions (biofilm, planktonic mid-log and
planktonic stationary), of which 60 and 48 proteins were found to be upregulated or downregulated, respectively, in biofilms relative to planktonic conditions. The
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BipA expression during infection
To determine whether BipA is expressed during natural infection,
naive adult BALB/c mice were infected intranasally with B. pertussis
strain B1917. Seven days after infection, bacteria were isolated from
the lungs and gene expression of bipA was analyzed by quantitative
polymerase chain reaction and compared to Bvg1, Bvgi and Bvg2 in
vitro conditions. As a negative control, the kpsT gene encoding a Bvg2
protein involved in capsule biosynthesis was included.40 Tran-
scriptional analysis showed that bipA is expressed in the lungs of mice,
at a level also observed under virulent in vitro Bvg1 and Bvgi condi-
tions (Figure 3A). Thus, these data indicate that BipA is expressed
during respiratory infection in mice.
To investigate whether BipA was also expressed during infection of
humans, a panel of convalescent sera from individuals who were
recently infected with B. pertussis was used to measure rBipA-specific
antibody responses. We used serum from individuals with anti-Ptx
titers above 400 ELISA Units per milliliter, as this level is strongly
indicative of recent infection.41 Sera from humans with undetectable
titers of anti-Ptx antibodies were chosen as negative control. Analysis
of these serum samples indicated that infection of humans also results
in antibodies to BipA (Figure 3B), suggesting that BipA is expressed
and immunogenic during infection.
BipA is a protective B. pertussis antigen
To determine the protective effects of BipA, we constructed a recom-
binant His-tagged fusion protein of BipA (rBipA). After purification
and refolding, the purity of the produced protein was confirmed by
Coomassie staining and immunoblotting (Supplementary Figure S1).
rBipA was then adjuvanted with Alhydrogel and used as stand-alone
antigen (5 mg) to vaccinate female adult BALB/c mice. Mice were
immunized 23 in 2-week intervals, after which they were challenged
by intranasal infection with B1917. Vaccination with rBipA resulted in
a small but significant reduction of bacterial load in the lungs as
compared to the PBS-vaccinated mice (Figures 4A and 4B, 5.4 and
3.4-fold at days 3 and 7, respectively) which was not observed in the
nasopharynx (Figures 4C and 4D). Thus, these data show that rBipA is
able to reduce bacterial load.
BipA-specific antibody responses
To determine the role of antibody-mediated protection by rBipA, an
ELISA was performed using sera from vaccinated mice. Figure 5A
shows that vaccination with rBipA induced high levels of rBipA-spe-
cific IgG. Similarly, rBipA-specific antibodies were also detected in
serum from biofilm-vaccinated mice, while these were below the detec-
tion limit in serum derived from mice vaccinated with planktonic
Table 1 Biofilm-associated proteins and vaccine candidate selection criteria
General information
Fold changea Protein abundance (emPAI values)b
Predicted
localizationc
Cytosol Membrane Cytosol Membrane
ORF Gene Protein name BF/ML BF/ST BF/ML BF/ST BF ML ST BF ML ST
BP1112 bipA Bordetella intermediate protein A 5.41 4.63 4.71 7.43 1.19 0.21 0.36 3.36 0.61 0.38 Om
BP0878 Phospholipase — — 3.76 3.74 — — — 0.32 — — Om
BP0038 gloA Lactoylglutathione lyase 12.48 9.00 9.00* 3.13* — — — — — — C
BP0782 Exported protein — — 3.90 13.56 — — — — — — Un
BP0901 Oxidoreductase 5.73 7.33 — — 0.07 — — — — — C
BP1315 Universal stress family protein 3.81 7.89 3.03* 2.27* 1.67 1.25 0.81 1.71 1.11 1.64 C
BP1519 fba Fructose-bisphosphate aldolase 3.83 11.15 21.33 21.32 4.96 2.16 1.12 1.61 1.47 1.95 C
BP2039 Amidase 3.62 9.89 — — — — — — — — C
BP2782 Lipoprotein — — 10.64 15.84 — — — 1.18 0.80 0.93 Un
BP2873 tctC Tripartite tricarboxylate transporter family
receptor
2.52 3.80 3.12 21.79 0.37 0.33 0.27 0.32 0.11 — P
BP2896 Hydrolase — — 4.19 6.81 — — — — — — C
Abbreviations: BF, biofilm; C, cytoplasmic; ML, mid-log; Om, outer membrane; ORF, open reading frame; P, periplasmic; ST, stationary; Un, unknown.
*Not significant (P.0.05).
a Fold change specifies the protein abundance ratio of the indicated conditions as determined using IDEAL-Q (Supplementary Table S1). ‘—’: protein not quantifiable.
b emPAI values37 were calculated based on the protein false discovery rate validation method of Weatherly38 (Supplementary Table S2). ‘—’: protein was not detectable.
c Localization prediction based on PSORTb v3.0.39
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Figure 3 bipA expression during infection. (A) Naive adult female BALB/c mice
were infected intranasally with B. pertussis strain B1917. After seven days,
bacteria were collected through BAL and used for in vivo transcriptional analysis
using bipA-specific primers as described in the text. Expression levels were
compared to in vitro Bvg1, Bvgi and Bvg2 conditions. The transcription data
are expressed as 402DCt value, which is a measure of expression relative to the
recA gene (DCt5Ct target–Ct recA). *P,0.05, **P,0.005, ***P,0.0005 rela-
tive to the Bvg2 condition; Student’s t-test with Welch’s correction. (B) Human
serum, from 10 confirmedB. pertussis-infected individuals (Bp1) and four non-
infected individuals (Bp2) was diluted and incubated on ELISA plates coated
with recombinant BipA or Ptx and the titers were determined. Horizontal lines
represent the geometrical mean. **P,0.005, ***P,0.0005 relative toBp- sera;
one-tailed Mann–Whitney U test. BAL, bronchoalveolar lavage.
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culture-derived membrane proteins (Figure 5A). Next, the ability of
serum and NL-derived rBipA-specific antibodies to bind its native epi-
topes on the surface of Bvg1 and Bvg2 B. pertussis was assessed by flow
cytometry. We found significant IgG-mediated opsonization of Bvg1 B.
pertussis using serum, but not NL, from rBipA-vaccinated mice
(Figure 5B). For aP-vaccinated mice, strong opsonization of Bvg1 B.
pertussis was observed with serum IgG and NL IgG and IgA
(Figures 5B–5D). Both aP- and rBipA-induced antibodies showed sig-
nificantly reduced binding to Bvg2 bacteria, which confirms the low
expression of these antigens by Bvg2-phase bacteria. These data show
that rBipA vaccination-induced antibodies recognize native BipA epi-
topes. Since IgG binding alone does not necessarily reflect the quality of
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Figure 4 Immunization with rBipA protects againstB. pertussis infection. Naive adult female BALB/cmice were subcutaneously immunized with rBipA or controls as
described in Figure 1 and infected intranasally with 23107 CFU of B. pertussis strain B1917. The bacterial load in the lungs and nose was quantified three (A and C)
and seven (B and D) days after challenge. Each symbol represents one mouse. Horizontal lines represent the mean. Dashed lines indicate the lower limit of detection.
**P,0.005 difference between rBipA and aP and between vaccinated and PBS control mice; two-tailed Mann–Whitney U test.
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Figure 5 Bacterial opsonization by BipA-specific antibodies. (A) Post-immunemouse sera (day 28) were used to determine the amount of total IgG specific for rBipA
using an ELISA. Each symbol represents one mouse and the geometrical mean is represented by a horizontal line. Dashed lines indicate the lower limit of detection
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the subsequent antibody response,42 the subtype distribution of the
opsonizing IgG molecules was also determined using a whole-cell
ELISA.31 Analysis of the IgG1, IgG2a and IgG2b response showed that
rBipA and aP antigen-specific antibodies were predominantly of the
phagocytosis-mediating IgG1 subtype43,44 (Figure 5E).
DISCUSSION
The recent resurgence of B. pertussis infections is of significant con-
cern. The observation that Prn negative strains are now increasingly
being isolated from patients with whooping cough12–14 highlights the
importance of identifying novel pertussis antigens. All current B. per-
tussis antigens used in aP vaccines have been derived from planktonic
grown bacteria. In this study, we focused on a novel class of proteins
which are upregulated in biofilms. Vaccination with planktonic and
biofilm-derived proteins may target different steps in infection and
broaden immunity. While biofilm formation has been suggested to be
important for successful B. pertussis infection,15,16 the ability of bio-
film-antigens to protect against infection has not been evaluated.
We showed that mice immunized with membrane proteins derived
from biofilm bacteria are protected against respiratory B. pertussis
infection and that the degree of protection was not significantly dif-
ferent from mice immunized with planktonic culture-derived mem-
brane proteins (Figure 1). This observation suggests that pertussis
biofilms are a potential target for vaccination, similar to other respir-
atory pathogens such as Pseudomonas aeruginosa.45 To characterize
the antigenic composition of a biofilm, we compared the biofilm and
planktonic proteomes of a representative strain of the P3 lineage
(B1917) which has recently spread worldwide.11
We found 48 proteins which were downregulated in biofilms.While
these proteins did not include any of the antigens present in current
aPs, a relatively high proportion of these proteins represent Bvg1
phase, virulence-associated proteins.10 This suggests that heterogen-
eous populations are involved in infections,46 even with respect to
virulence-associated proteins. Therefore, inclusion of highly expressed
biofilm proteins in new vaccine formulationsmay enhance the efficacy
of pertussis vaccines by broadening the immune response to different
phases of infection. Sixty proteins were identified as more abundantly
present in biofilms, the majority of which represented ribosomal pro-
teins involved in protein synthesis. However, the majority of these
ribosomal proteins were biofilm-upregulated only when compared
to stationary growth, and were expressed at similar levels under
mid-log conditions (Supplementary Table S1). This suggests that bio-
film formation requires high levels of de novo synthesis of proteins,
similar to mid-log bacteria.20,47 Of these 60 proteins, only 11 were
upregulated when compared to both mid-log and stationary plank-
tonic growth conditions. Moreover, only two of these were predicted
to be surface-accessible, i.e. a phospholipase (BP0878) and BipA.
Although BP0878 may also have vaccine potential,48 we only assessed
the vaccine potential of BipA because it was more abundantly
expressed under biofilm conditions. Further, BipA was also found
upregulated in Tohama I biofilms relative to planktonic cultures sug-
gesting that expression of BipA is a common signature of Bordetella
biofilms.18 BipA shows a large degree of amino-acid sequence identity
with the biofilm-associated proteins of Staphylococcus aureus49 and
Acinetobacter baumannii,50 which mediate cell-to-cell interactions
within biofilms 51 (36% and 33% identity, respectively). Importantly,
vaccination with biofilm-associated protein derived from A. baumannii
has been shown to protect against infection.52 BipA may play a similar
role in B. pertussis biofilm formation during infection. Some clues
towards a role for BipA during infection were established in this work.
For instance, we showed that during natural infection, BipA was
expressed at high levels in the lungs of mice and that infection resulted
in BipA-specific serum antibodies in humans (Figure 3). Challenge
experiments showed that vaccination with rBipA induced significant
protection to lower respiratory tract infection (Figure 4), which
was associated with the presence of high amounts of opsonizing, pro-
tection-associated IgG1 antibodies43,44 (Figure 5). Significant amounts
of rBipA antibodies were also detected in serum from mice vaccinated
with biofilm membrane proteins, but not in mice vaccinated with pro-
teins derived from planktonic bacteria, suggesting that BipA is highly
expressed in B. pertussis biofilms and immunogenic. An important
question is how efficacious BipA will be in natural B. pertussis popula-
tions which consist of different strains. The strain used to assess the
vaccine efficacy of rBipA, is a representative of the P3 lineage, the
members of which have spread worldwide in the last 10–15 years repla-
cing the resident P1 strains.11,53 In many countries, P3 strains are found
in frequencies of 60%–100%. Further, immune escape from BipA anti-
bodies seems unlikely, as in a worldwide collection of 343 B. pertussis
strains, only one protein variant was found (designated BipA2),53 which
differed in only one amino acid from the BipA variant used in this
study. Further research is needed to establish the exact mechanisms
by which antibodies to biofilms and BipA in particular interfere with
infection, and whether protection by BipA can be enhanced through the
use of alternative vaccine adjuvants or vaccination routes.
Membrane proteins extracted from biofilm or planktonic grown
cells conferred protection in the mouse lung, while only the biofilm
extract induced rBipA antibodies, albeit at lower levels compared to
vaccination with rBipA. Clearly, these planktonic fractions harbor
other protective antigens. Proteomic analyses of these fractions
revealed high expression of many virulence associated factors, includ-
ing those who have been shown to confer protection in humans (i.e.,
Ptx, Fim3, Prn and FHA), integral outer membrane proteins and
autotransporters (Supplementary Tables S1 and S2). Further frac-
tionation of these samples may elucidate the distinct role of these
antigens and reveal additional vaccine candidates.
Taken together, this work provides evidence that vaccination
against B. pertussis biofilms induces protection to infection. While
further research is still needed to optimize immunity, a strategy by
which multiple steps in infection are targeted, including biofilm
formation, represents an attractive approach to improve pertussis
vaccines. The inclusion of BipA in novel vaccines may thus provide
an additional level of protection to current aPs and thereby enhance
the efficacy of pertussis vaccination.
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